Teleflex Incorporated (TFX)

NYSE: TFX · USD

$138

-0.51 (-0.4%)· Recorded snapshot

英文原文ZH

翻译期间显示英文原文

此报告尚未翻译。翻译队列赶上后请在几分钟内刷新。

StockMarketAgent Research · Analyzed 2026-10-16

Our latest published analysis: TFX rated Hold

Teleflex Incorporated's published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$123 / share

Potential value

$191 / share

Upside to FV

-5.8%

from $138

Moat

6.8/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$5.5B
Revenue (ttm)	2.3B
Net income (ttm)	-1B
EPS (ttm)	-$23.4
Shares out	42.4M
P/E (forward)	11.0x
Dividend	$1.36 (0.98%)
Volume	501,819
Beta	0.83

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 2.3B
Net income (ttm): -1B
EPS (ttm): -$23.4
P/E (forward): 11.0x
Market cap: $5.5B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$2.81B	$2.79B	$1.71B	$1.70B	$1.99B	-8.2%
Gross profit	$1.55B	$1.53B	$1.04B	$1.04B	$1.12B	-7.8%
Operating income	$628.1M	$499.7M	$258.7M	$103.7M	$118.4M	-34.1%
Net income	$485.4M	$363.1M	$356.3M	$69.7M	$-905.6M	—
EPS (diluted)	$10.23	$7.68	$7.53	$1.48	$-20.25	—
EBITDA	$853.8M	$730.8M	$761.2M	$433.6M	$302.5M	-22.8%
R&D	$130.8M	$153.8M	$113.6M	$109.0M	$144.8M	+2.6%
SG&A	$860.1M	$863.7M	$622.7M	$674.5M	$720.2M	-4.3%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	39.4x	10.8x	101.6%	+6.1%	+28.5%	卖出
ABNB	Airbnb, Inc.	97.8B	37.5x	7.4x	16.8%	+24.4%	+28.5%	卖出
ADBE	Adobe Inc.	97.1B	13.9x	3.7x	57.2%	+11.5%	-30.7%	强力买入
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	卖出
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	减持
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	减持

Base and Bull scenarios

Base60%

Price target

$122.83

-5.8% from spot

Teleflex delivers on its stated restructuring objectives, stabilizing Interventional growth while Vascular and Surgical maintain steady procedural gains. Operating margins expand from guided 19.0% in FY2026 to 21.0% in FY2027 and 23.0% by FY2030 as transition service agreements offset separation friction and restructuring generates $50M in pre-tax savings. Debt paydown of $800M and $1.0B in cumulative share repurchases support consensus FY2027 EPS of $10.95, yielding a mid-case fair value of $122.83.

Revenue growth CAGR of approximately 4.0% through FY2030 (FY2026 guided at 13.8% GAAP, FY2027 at 4.3%, tapering to 3.5%).
Adjusted operating margin expands from guided ~19.0% in FY2026 to 21.0% in FY2027 and reaches 23.0% steady-state by FY2030.
Reinvestment rates moderate from 28% in FY2026 to 20% in FY2030, generating $272M to $413M in FCFF.
Terminal P/E multiple of 14.0x, EV/Revenue multiple of 2.5x, and discount rate (WACC) of 9.67%.

Bull20%

Price target

$190.97

+46.4% from spot

Biotronik integration bottlenecks resolve rapidly by year-end 2026, allowing Interventional to re-accelerate alongside Vascular (8.0% Q2 growth) and Surgical (9.2% Q2 growth) franchises. Transition services and restructuring programs eliminate all stranded corporate costs, expanding operating margin to 24.5%. Proceeds from all three divestitures fund the complete $1.0B repurchase and $800M debt reduction, driving adjusted EPS past consensus and supporting a bull-case valuation of $190.97.

Pro forma constant currency revenue growth re-accelerates to 5.5%-6.5% annually across the 5-year forecast horizon.
Adjusted operating margin expands beyond steady-state target to reach 24.5% by FY2030 through operational leverage and restructuring savings.
Divestiture proceeds fund $800M debt paydown and complete the $1.0B buyback, reducing share count toward 41.5M shares.
Terminal P/E multiple expands to 16.0x as business quality improves and Freesolve BIOMAG-II data impresses in late 2027.

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($122.83). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.0%	2.3%	2.5%	2.8%	3.0%
7.9%	$134	$137	$141	$145	$149
8.4%	$125	$128	$131	$134	$138
8.9%	$118	$120	$123	$126	$129
9.4%	$111	$113	$116	$118	$120
9.9%	$105	$107	$109	$111	$113

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E11

P25 n/aP50 n/aP75 n/a

Trailing P/E2,777.8

P25 n/aP50 n/aP75 n/a

ROE-0.7

P25 n/aP50 n/aP75 n/a

ROIC3.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All TFX indicators

Market & fundamental data

Available fields

269

Groups with data

Currency

USD

Showing 269 of 269 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000096943
Company name	Teleflex Incorporated
Country	United States
Country code	US
CUSIP number	879369106
Earnings date	2026-11-05
Earnings time	bmo
Employees	15,500
Employees change	1,400
Employees growth	9.93%
Enterprise value	$8.5B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1943
Industry	Medical Instruments & Supplies
Is primary listing	Yes
Is SPAC	No
ISIN number	US8793691069
Last 10-K release date	2026-02-27
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split date	1997-06-17
Last stock split type	Forward
Market cap	$5.9B
Market cap category	Mid-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$138.48
Price currency	USD
Sector	Healthcare
SIC code	3841
Stock price date	2026-10-28
Symbol	TFX
U.S. state	Pennsylvania
Website	https://www.teleflex.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	15.83x
Average P/E ratio (10Y)	49.94x
Average P/E ratio (3Y)	45.72x
Average P/E ratio (5Y)	38.45x
Earnings yield	-16.91%
EV/EBIT	42.68x
EV/EBITDA	20.93x
EV/FCF	25.85x
EV/Sales	3.75x
FCF / EV yield	3.87%
FCF yield	5.6%
Forward EV/Sales	3.66x
Forward P/E	15.03x
Forward P/S	2.53x
Industry forward P/E	22.69x
Industry P/E	75.18x
P/(FCF - SBC) ratio	19.38x
P/(OCF - SBC) ratio	15.47x
P/B ratio	2.03x
P/FCF ratio	17.87x
P/OCF ratio	14.49x
P/S ratio	2.59x
PEG ratio	0.74x
Price/EBITDA ratio	14.47x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	8.79%
EBITDA margin	17.92%
FCF margin	14.51%
Gross margin	55.11%
Operating margin	8.79%
Pretax margin	-2.82%
Profit margin	-45.76%
Profit per employee	$-66,560
Profitable quarters	1
Revenue per employee	$145,453
ROA	1.75%
ROA (5Y)	3.09%
ROCE	3.27%
ROE	-0.7%
ROE (5Y)	5.86%
ROIC	3.6%
ROIC (5Y)	5.45%
SBC / revenue	1.14%
Tax / revenue	-1.71%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth (Q)	-17.3%
EPS growth years	0
FCF growth	-26.53%
FCF growth (QoQ)	165.59%
FCF growth 3Y	0.1%
FCF growth 5Y	-7.35%
Gross profit growth	71.12%
Gross profit growth (Q)	25.01%
Gross profit growth 3Y	-7.91%
Gross profit growth 5Y	-3.16%
Net income growth (Q)	-18.67%
Net income growth years	0
OCF growth	-21.6%
OCF growth (Q)	1,118.59%
OCF growth (QoQ)	92.42%
OCF growth 10Y	0.78%
OCF growth 3Y	-0.73%
OCF growth 5Y	-6.61%
Operating income growth	1.16%
Operating income growth (Q)	-43.67%
Operating income growth 3Y	-27.77%
Operating income growth 5Y	-17.04%
Revenue growth	110.94%
Revenue growth (Q)	28.88%
Revenue growth (QoQ)	4.03%
Revenue growth 10Y	2.18%
Revenue growth 3Y	-8.04%
Revenue growth 5Y	-3.45%
Revenue growth quarters	4
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-76.1M
Depreciation and amortization	$205.8M
EBIT	$198.1M
EBITDA	$403.9M
EPS	$-23.41
FCF per share	$7.72
Financing cash flow	$567.7M
Free cash flow	$327.1M
Free cash flow minus SBC	$301.5M
Gross profit	$1.2B
Income taxes	$-38.5M
Investing cash flow	$-889.4M
Net borrowing	$917.4M
Net cash flow	$9.2M
Net income	$-1B
Operating cash flow minus SBC	$377.6M
Operating income	$198.1M
Revenue	$2.3B
Stock-based compensation	$25.6M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.12
Book value per share	$68.55
Debt / EBITDA	6.81
Debt / equity	1.01
Debt / FCF	8.98
Goodwill	$2.3B
Interest coverage	1.74
Long-term assets	$4.9B
Long-term liabilities	$3.2B
Net cash (debt)	$-2.6B
Net cash / market cap	-44.71%
Net debt / EBITDA	6.47
Net debt / equity	0.9
Net debt / FCF	7.99
Piotroski F-Score	5
Property, plant and equipment	$552.8M
Shareholders' equity	$2.9B
Tangible book value	$-836.6M
Tangible book value per share	$-19.74
Total assets	$6.8B
Total cash	$323.9M
Total debt	$2.9B
Total liabilities	$3.9B
WACC	6.9%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.32
Current assets	$1.9B
Current liabilities	$720.4M
Current ratio	2.6
Inventory turnover	1.94
Net working capital	$934.6M
Quick ratio	0.96
Working capital	$1.2B
Working capital turnover	2.08

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	4.13%
Dividend growth	0%
Dividend growth (10Y)	0%
Dividend growth (3Y)	0%
Dividend growth (5Y)	0%
Dividend growth years	0
Dividend payment date	2026-09-30
Dividend payment years	50
Dividend payout frequency	Quarterly
Dividend per share	$1.36
Dividend yield	0.98%
Ex-dividend date	2026-08-14
FCF payout ratio	17.62%
Last dividend	$0.34
Shareholder yield	5.11%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-0.67%
10Y return CAGR	0.56%
10Y total return	5.75%
150-day SMA	$130.15
15Y price change	130.8%
15Y return CAGR	6.7%
15Y total return	164.51%
1D price change	-0.37%
1M price change	13.44%
1M total return	13.44%
1W price change	6.2%
1W total return	6.2%
1Y price change	4.47%
1Y return CAGR	5.64%
1Y total return	5.64%
20-day SMA	$129.22
200-day SMA	$124.79
20Y price change	122.21%
20Y return CAGR	5.4%
20Y total return	186.21%
3M price change	5.67%
3M total return	5.93%
3Y price change	-22.81%
3Y return CAGR	-7.43%
3Y total return	-20.68%
50-day SMA	$131.12
50-day SMA vs 200-day SMA	50over200
52-week high	$145.00
52-week high date	2026-08-06
52-week low	$100.18
52-week low date	2026-01-20
5Y price change	-62.19%
5Y return CAGR	-17.06%
5Y total return	-60.74%
6M price change	2.53%
6M total return	3.05%
All-time high	$449.38
All-time high date	2021-04-28
All-time low	$0.11
All-time low date	1970-07-15
Average true range (ATR)	$3.75
Average volume	664.2K
Beta (1Y)	0.7
Beta (2Y)	0.57
Beta (5Y)	0.83
Change from 52-week high	-4.5%
Change from 52-week low	38.23%
Change from all-time high	-69.18%
Change from all-time low	125,905.46%
Change from open	-0.19%
Day's gap	-0.18%
Dollar volume	$69.5M
High price	$140.02
Low price	$137.10
Monthly RSI	46.36
Open price	$138.75
Position in 52-week range	47.26%
Premarket change	-0.01%
Premarket close	$139.00
Premarket price	$138.98
Premarket volume	9.3K
Previous close	$139.00
Price vs 150-day SMA	6.4%
Price vs 20-day SMA	7.16%
Price vs 200-day SMA	10.97%
Price vs 50-day SMA	5.61%
Relative volume	0.77
RSI	68.39
Sharpe ratio	0.24
Sharpe ratio (3Y)	-0.18
Sharpe ratio (5Y)	-0.49
Sortino ratio	0.49
Sortino ratio (3Y)	-0.09
Sortino ratio (5Y)	-0.5
Volume	501.8K
Weekly RSI	58.6
YTD price change	13.47%
YTD total return	14.38%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	42.2M
Float percentage	99.62%
Shares change (QoQ)	-1.35%
Shares change (YoY)	-4.13%
Shares held by insiders	0.3%
Shares held by institutions	113.91%
Shares outstanding	42.4M
Short % of float	9.6%
Short % of shares	9.56%
Short ratio	4.9 days

Deeper analysis on TFX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this TFX report

What is the latest published TFX stock rating?

Teleflex Incorporated is shown with Hold in the latest published report, analyzed 2026-10-16. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full TFX analysis?

The full latest published report, analyzed 2026-10-16, lives at /stocks/TFX/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for TFX?

The latest published report analyzed 2026-10-16 gives TFX a fair value of USD 123 and a potential value of USD 191. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the TFX page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-16). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

HoldTFX · Fair value $123-5.8%

Read full analysis →

Teleflex Incorporated (TFX)

Our latest published analysis: TFX rated Hold

Price

Financial snapshot

Fair-value bridge

Latest news · TFX

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All TFX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on TFX

Frequently asked questions

评级历史

Category	Score	Reading
Valuation	4.5
Management	7.5
Balance Sheet	6.5
Profitability	1.5
Revenue Growth	7.5
Risk Assessment	6.5
Competitive Moat	6.8
Earnings Quality	1.5
Capital Efficiency	4.5